TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10636350

Group type: EXPERIMENTAL
Intervention: 2 g of cefotaxime sodium diluted in 100 mL of isotonic sodium chloride solution (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 10 mL of isotonic sodium chloride solution in 100 mL of saline (Group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 9190979

Group type: EXPERIMENTAL
Intervention: Retroperitoneal drainage (Group A, 68 patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: No retroperitoneal drainage (Group B, 69 patients)
Number of subjects: 137
Study: 1541883

Group type: EXPERIMENTAL
Intervention: Bipolar diathermy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 49
Study: 4041323

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution 4 ml without glucose
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% bupivacaine solution 4 ml with glucose
Number of subjects: 20
Study: 29960633

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 470
Study: 27157678

Group type: EXPERIMENTAL
Intervention: toggle recoil spinal manipulation
Number of subjects: 51

Group type: COMPARATOR
Intervention: sham procedure
Number of subjects: 51
Study: 24935040

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of mobilized BMSCs
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of mobilized BMSCs
Number of subjects: 58

Group type: COMPARATOR
Intervention: Subcutaneous granulocyte colony-stimulating factor injections
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline injections only
Number of subjects: 58
Study: 22810376

Group type: EXPERIMENTAL
Intervention: Radiological catheter insertion using fluoroscopic guidance under local anaesthesia
Number of subjects: 113

Group type: COMPARATOR
Intervention: Laparoscopic catheter insertion under general anaesthesia
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall catheter survival
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Subject survival
Number of subjects: 113

Group type: COMPARATOR
Intervention: Laparoscopic group
Number of subjects: 113
Study: 20400900

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 250 mg aspirin
Number of subjects: 234
Study: 17239638

Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg twice daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of azelastine and montelukast
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 17
Study: 15925031

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 12
Study: 15315030

Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg once a week
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9861095

Group type: EXPERIMENTAL
Intervention: HD-PNI risk (n = 208, 18%)
Number of subjects: 1527
Study: 8896852

Group type: EXPERIMENTAL
Intervention: Propofol patient-controlled sedation (PCS) (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No intraoperative sedation (n = 27)
Number of subjects: 55
Study: 30908497

Group type: EXPERIMENTAL
Intervention: Head cooling (temperature-controllable cooling sheet at 25C)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (temperature at 35C)
Number of subjects: 14
Study: 29944712

Group type: EXPERIMENTAL
Intervention: SDM-Digital Intake (SDM-DI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intake As Usual (IAU)
Number of subjects: 200
Study: 27583108

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (Group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pregabalin or gabapentin (Group B)
Number of subjects: 54
Study: 25100135

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m², 3 h, i.v.) with rifampin (600 mg/day, 6 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trabectedin (0.58 mg/m², 3 h, i.v.) with ketoconazole (200 mg, twice-daily, 15 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Trabectedin monotherapy (1.3 mg/m², 3 h, i.v.)
Number of subjects: 20
Study: 22545740

Group type: EXPERIMENTAL
Intervention: Therapist-supported bibliotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 55
Study: 18952538

Group type: EXPERIMENTAL
Intervention: OAT (omeprazole, amoxicillin, tinidazole)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: OCT (omeprazole, clarithromycin, tinidazole)
Number of subjects: 250
Study: 17366797

Group type: EXPERIMENTAL
Intervention: Surgery (esophagectomy with resection of the lesion and 5 cm margin, surrounding lymph nodes > or = 5 mm)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Radiotherapy (LCAHFR with total dose of 68.4-71.0 Gy)
Number of subjects: 269
Study: 14728211

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) model
Number of subjects: 7457

Group type: EXPERIMENTAL
Intervention: SVM model with relative sentence location feature
Number of subjects: 7457

Group type: COMPARATOR
Intervention: Linear Classifier model
Number of subjects: 7457

Group type: EXPERIMENTAL
Intervention: SVM model trained on structured abstracts
Number of subjects: 7457
Study: 11064608

Group type: EXPERIMENTAL
Intervention: Lidocaine 20.0 mg in 2.0 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine 5 mg in 2.0 ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline 2.0 ml
Number of subjects: 12
Study: 8984600

Group type: EXPERIMENTAL
Intervention: Xylometazoline combined with S-carboxymethylcysteine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylephrine combined with dimethindene maleate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Benzydamine or phenylephrine combined with dimethindene maleate
Number of subjects: 60
Study: 1422657

Group type: EXPERIMENTAL
Intervention: Computed radiography using a 2K x 2K, 12‐bit storage phosphor plate system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Edge-enhanced computed images
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 50
Study: 3891227

Group type: EXPERIMENTAL
Intervention: Enhanced visit adherence methods (appointment reminders, assistance with transportation, minimal waiting times, newsletters, continuity of care, involvement of family members, close contact with private physicians)
Number of subjects: 3837

Group type: EXPERIMENTAL
Intervention: Visit adherence in BHAT
Number of subjects: 3837
Study: 31977667

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride extended release
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Low-dose estradiol
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Omega-3 supplementation
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Vaginal estradiol tablet
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Vaginal moisturizer
Number of subjects: 1300
Study: 29873422

Group type: EXPERIMENTAL
Intervention: Model-based RSA in total wrist arthroplasties
Number of subjects: 40

Group type: COMPARATOR
Intervention: Model-based RSA with less than four bone markers
Number of subjects: 40
Study: 26784123

Group type: EXPERIMENTAL
Intervention: Reminder letter sent a few days before the breast screening appointment
Number of subjects: 22828

Group type: COMPARATOR
Intervention: No reminder letter (control)
Number of subjects: 22828
Study: 24812072

Group type: EXPERIMENTAL
Intervention: High-fat meal (500, 1000, and 1500 kcal, 60.5% energy from fat)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-fat meal (1500 kcal)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-fat meal (1000 kcal to 1500 kcal)
Number of subjects: 37
Study: 22147061

Group type: EXPERIMENTAL
Intervention: High-risk information
Number of subjects: 286

Group type: COMPARATOR
Intervention: Low-risk information
Number of subjects: 286
Study: 20200432

Group type: EXPERIMENTAL
Intervention: Antioxidant micronutrient combination (800 mg dl‐alpha‐tocopherol acetate, 24 mg beta‐carotene, 1.0 g vitamin C, 200 microg l‐selenomethionine, 7.2 mg riboflavin, 80 mg niacin, 60 mg zinc, 5 mg manganese) given daily over 4 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Antioxidant micronutrient combination
Number of subjects: 47
Study: 19088765

Group type: EXPERIMENTAL
Intervention: +CHO
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: +CAF/-CHO
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: -CAF/+CHO
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: +CAF/+CHO
Number of subjects: 9

Group type: COMPARATOR
Intervention: -CAF/-CHO
Number of subjects: 9
Study: 15899687

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 12780345

Group type: EXPERIMENTAL
Intervention: MUFA-enriched diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: HCLF diet
Number of subjects: 31
Study: 10499750

Group type: EXPERIMENTAL
Intervention: Neostigmine (500 microg) + mepivacaine (500 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mepivacaine (500 mg) + saline (0.9%, 1 mL)
Number of subjects: 34
Study: 8890061

Group type: EXPERIMENTAL
Intervention: Type 1 test food (20 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Type 2 test food (40 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Type 3 test food (1.0 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Type 4 test food (0.5 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chewing order of test foods
Number of subjects: 13
Study: 1800923

Group type: EXPERIMENTAL
Intervention: Cryotherapy for Retinopathy of Prematurity (ROP)
Number of subjects: 4099
Study: 6407402

Group type: EXPERIMENTAL
Intervention: Benoxaprofen 600 mg orally daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 40
Study: 29921786

Group type: EXPERIMENTAL
Intervention: Exercise at 70% V˙O2Peak (HIGH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise at 40% V˙O2Peak (LOW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest (CONTROL)
Number of subjects: 12
Study: 27639738

Group type: EXPERIMENTAL
Intervention: PCI using XIENCE cobalt‐chromium everolimus‐eluting stents (CoCr‐EES)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Graft)
Number of subjects: 1900
Study: 24920891

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 500 μg twice daily for 6 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22773616

Group type: EXPERIMENTAL
Intervention: Counseling sessions
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intervention components
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PST components
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adherence to study objectives
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adherence to PST theory
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Counselor competence
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Counselor performance
Number of subjects: 65
Study: 20962624

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (HD-IVIG)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulin (low-IVIG)
Number of subjects: 646
Study: 18287826

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 123
Study: 15723889

Group type: EXPERIMENTAL
Intervention: Social support interventions
Number of subjects: 12
Study: 15643747

Group type: EXPERIMENTAL
Intervention: Comprehensive program
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Less comprehensive program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Knowledge and reported behavior correlation
Number of subjects: 186
Study: 11114219

Group type: EXPERIMENTAL
Intervention: 600 mg/d OXC
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: 1200 mg/d OXC
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: 2400 mg/d OXC
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 8788262

Group type: EXPERIMENTAL
Intervention: Dietary fish oil (FO) supplementation (5 food bars daily for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Safflower oil (SO) (control group)
Number of subjects: 19
Study: 1638170

Group type: EXPERIMENTAL
Intervention: brofaromine (150 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 6465821

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous metamizole (2.5 g)
Number of subjects: 60
Study: 29868796

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (methylprednisolone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ozone (O2‐O3) injection
Number of subjects: 30
Study: 29401242

Group type: EXPERIMENTAL
Intervention: Positive contact with one older adult
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Increase in IOS
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Decrease in incompetence stereotypes
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Incompetence stereotypes
Number of subjects: 302
Study: 28604516

Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) for 16 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) and complementary foods
Number of subjects: 82
Study: 26226283

Group type: EXPERIMENTAL
Intervention: Trans-contextual model-based intervention (12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 22631049

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 78

Group type: COMPARATOR
Intervention: LOS/HCTZ
Number of subjects: 78
Study: 21477416

Group type: EXPERIMENTAL
Intervention: Quetiapine IR (300 mg/d on days 9-12)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg/d on days 5-8)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study: 19500999

Group type: EXPERIMENTAL
Intervention: Single dose of Pro‐Stat 64 supplementation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Double dose of Pro‐Stat 64 supplementation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 6
Study: 16518128

Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate
Number of subjects: 21
Study: 15273006

Group type: EXPERIMENTAL
Intervention: Confrontation of racial bias from either target or nontarget group member
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confrontation of gender bias from either target or nontarget group member
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target confrontations (from Black or female)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nontarget confrontations (from White or male)
Number of subjects: 0
Study: 11020910

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg mesulid, Pfizer)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg, Bayer)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9025767

Group type: EXPERIMENTAL
Intervention: VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)
Number of subjects: 94

Group type: COMPARATOR
Intervention: MMPP (melphalan, ranimustine, procarbazine, prednisolone)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: VMCP to MMPP crossover
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MMPP to VMCP crossover
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: VMCP
Number of subjects: 94

Group type: COMPARATOR
Intervention: MMPP
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: MP therapy (MPH/PSL combination)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AT (alternating therapy with VMCP and MMPP)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Plateau phase
Number of subjects: 94
Study: 8331248

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25% ophthalmic suspension (preserved with benzalkonium chloride)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25% ophthalmic suspension (unpreserved)
Number of subjects: 27
Study: 3579256

Group type: EXPERIMENTAL
Intervention: 500 mg every 6 h (five doses)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1,000 mg every 12 h (three doses)
Number of subjects: 11
Study: 28666964

Group type: EXPERIMENTAL
Intervention: Fournier® 200 mg capsule
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lipidil® 145 mg tablet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HME 160 mg tablet
Number of subjects: 3

Group type: COMPARATOR
Intervention: In vivo pharmacokinetic profiles
Number of subjects: 3
Study: 27629349

Group type: EXPERIMENTAL
Intervention: Extracellular space contrast agents (ECSCAs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blood-pool contrast agent (BPCA)
Number of subjects: 60
Study: 24429305

Group type: EXPERIMENTAL
Intervention: Integrated treatment arm (ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sequential treatment arm (ART after completing anti-tuberculosis treatment)
Number of subjects: 23
Study: 22395586

Group type: EXPERIMENTAL
Intervention: Combination of essential oil of Melaleuca alternifolia and organically bound iodine (TTO-I)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Iodine alone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Essential oil of Melaleuca alternifolia (TTO)
Number of subjects: 53
Study: 20690152

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 212
Study: 18684548

Group type: EXPERIMENTAL
Intervention: Compression to ventilation ratio 30:2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Compression to ventilation ratio 15:2
Number of subjects: 18
Study: 15985728

Group type: EXPERIMENTAL
Intervention: Indigenous recombinant streptokinase (Shankinase, r-SK)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Natural streptokinase (Streptase, n-SK)
Number of subjects: 150
Study: 12682335

Group type: EXPERIMENTAL
Intervention: MRS brain metabolite ratio N-acetylaspartate (NAA)/myo-inositol (mI) in subjects with small hippocampal volumes
Number of subjects: 60

Group type: COMPARATOR
Intervention: MRS brain metabolite ratio N-acetylaspartate (NAA)/myo-inositol (mI) in other subjects
Number of subjects: 60
Study: 10550740

Group type: EXPERIMENTAL
Intervention: sublingual‐swallow immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 8889480

Group type: EXPERIMENTAL
Intervention: H-wave therapy at 16 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: H-wave therapy at 60 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: H-wave therapy at 2 Hz
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 1792609

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 13
Study: 7215765

Group type: EXPERIMENTAL
Intervention: Fenoterol Hydrobromide
Number of subjects: 112
Study: 30790569

Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 419

Group type: COMPARATOR
Intervention: Foley balloon
Number of subjects: 419
Study: 27743214

Group type: EXPERIMENTAL
Intervention: Piezon Master 700 with NO PAIN technology
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mini Piezon without NO PAIN technology
Number of subjects: 100
Study: 25724644

Group type: EXPERIMENTAL
Intervention: Pradigastat (100 mg for 3 days followed by 40 mg for 7 days, 1 hour before meal)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 25
Study: 24582486

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 2 mg/mL per min) plus paclitaxel (60 mg/m(2)) every week for 18 weeks
Number of subjects: 810

Group type: COMPARATOR
Intervention: Carboplatin (AUC 6 mg/mL per min) plus paclitaxel (175 mg/m(2)) every 3 weeks for six cycles
Number of subjects: 810
Study: 18596290

Group type: EXPERIMENTAL
Intervention: Language-focused curriculum (LFC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prevailing curriculum
Number of subjects: 14
Study: 15507885

Group type: EXPERIMENTAL
Intervention: Oral defibrotide (800 mg/die)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 288
Study: 11331472

Group type: EXPERIMENTAL
Intervention: Imipenem (1.0 g plus cilastatin intravenously 3 times a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (delayed antibiotics)
Number of subjects: 90
Study: 9425396

Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (rhGH) replacement therapy at a dosage of 12.5 micrograms/kg/day (initial dosage during the first 4 weeks 6.25 micrograms/kg/day)
Number of subjects: 17
Study: 8245105

Group type: EXPERIMENTAL
Intervention: Non-acid-buffering prophylaxis therapy (6 patients)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard antacid or antacid/H2 histamine-blocking agent combination prophylaxis therapy (13 patients)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 3681765

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 34